Organism: Homo sapiens
Gene: 1550_at
Selected probe(set): 204599_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1550_at (204599_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.3198757
Number of Samples:20 / 19

Experimental	atopic dermatitis study 12 (non-lesional; adults)
	Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (non-lesional; children)
	Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):-2.2839622
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-2.237442
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 DICER1(-/-) cell sample
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.1738663
Number of Samples:20 / 18

Experimental	atopic dermatitis study 12 (lesional; adults)
	Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (lesional; children)
	Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):-2.1037016
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):1.9564209
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-18)
	Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):-1.8016758
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

Relative Expression (log2-ratio):1.5911827
Number of Samples:2 / 2

Experimental	T-cell activation study 1
	CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control	quiescent CD4+ T-cell sample
	Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

Relative Expression (log2-ratio):-1.5562048
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-1.5410051
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 DICER1(-/-) cell sample
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.